The copyright owner consents that copies of articles may be made for personal or internal use, or for the personal or internal use of specific clients, for those registered with the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, MA 01923; (978) 750-8400; www.copyright.com). This consent is given on the condition that the copier pay the stated per-copy fees through the Copyright Clearance Center, Inc., for copying beyond that permitted by Sections 107 and 108 of the US Copyright Law (Fair Use). This consent does not extend to other kinds of copying, such as copying for general distributio
Instructions to Authors
Authors:
All manuscripts submitted to Blood must be uploaded at Blood Manuscript Central.
Information for authors submitting manuscripts to Blood:
1. Editorial policies and procedures
2. Web uploading instructions
3. Blood Style Guide
4. Guidelines for Invited Reviews
Form needed for submitting new manuscripts: Author Statement
Forms needed for submitting revised manuscripts:
Checklist for revised online manuscripts
Copyright transfer form
1. EDITORIAL POLICIES AND PROCEDURES
Blood, the Journal of The American Society of Hematology, published in print and online, provides an international forum for the publication of original articles describing basic and clinical investigations in hematology. Acceptance of papers is based on the originality of the observation or investigation, the quality of the work described, the clarity of presentation, and the relevance to our readership. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and has not been submitted elsewhere for print or electronic publication consideration.
Authors should take care to exclude overlap and duplication in papers dealing with related materials. Copies of existing papers with potentially overlapping or duplicative material should be submitted together with the manuscript so that the Editors can judge suitability for publication. See also paragraph on Redundant or Duplicate Publication in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" at http://www.icmje.org/index.html.
Manuscripts will be reviewed by the Editors, members of the Editorial Board, or other expert reviewers. At the discretion of the Editors, the manuscript may be returned immediately without full review, if deemed not competitive or outside the realm of interests of the majority of the readership of the Journal. The decision (reject, invite revision, accept) letter will be conveyed through Blood Manuscript Central, coming directly from the Associate Editor who has assumed responsibility for the manuscript's review. Editorial decisions are based not just on technical merit of the work, but also on other factors such as the priority for publication and the relevance to the Journal's general readership. All papers are judged in relation to other submissions currently under consideration. Rebuttals to rejected manuscripts are strongly discouraged and requests for resubmission of rejected manuscripts are generally not granted.
NEW MANUSCRIPTS should be submitted online at the following URL: http://blood.manuscriptcentral.com. See detailed submission procedures online at http://www.bloodjournal.org/misc/webuploadinginstructions.shtml.
The Central Office address below is to be used for (a) mailing checks to cover the submission fee and (b) for sending camera-ready figures for accepted papers. The fax number listed below is to be used for providing the signed Author Statement immediately after the online submission of the manuscript:
Sanford J. Shattil, MD
Editor-in-Chief, Blood
1900 M Street, NW, Suite 200
Washington, DC 20036
Telephone: 202-776-0548
Fax: 202-776-0549
E-mail addresses:
editorial@hematology.org
production@hematology.org
publishing@hematology.org
Please note: The Blood e-mail addresses are for inquiries only; manuscripts must be submitted at the URL listed above.
Editorial office response. The successful online submission of the manuscript will be acknowledged via e-mail to the corresponding author. The corresponding author will receive the manuscript number, which should be cited in all correspondence (eg, on the faxed Author Statement) happening outside of Blood Manuscript Central, the online submission and review system.
Categories of manuscripts
Regular manuscripts. Manuscripts submitted as Regular Articles are expected to be concise, well organized, and clearly written. Starting July 1, 2003, maximum length is 5000 words of text, excluding tables, figure legends, and references, and submissions are limited to a total of 7 figures. Submissions exceeding these limits will not be considered for review and will be returned to the author. Abstracts must not exceed 200 words and should be a single paragraph with no sub-headings. Acceptance of Regular Articles is based on the originality, definitiveness, and importance of the findings to the field of hematology. Manuscripts that have passed an initial screening by the Editors are reviewed by two or more experts in the field. Detailed comments from the reviewers are generally returned to the authors. Manuscripts requiring extensive revision will be at a disadvantage for publication. Regular manuscripts will be published under the following scientific categories: Chemokines; Clinical Observations, Interventions, and Therapeutic Trials; Gene Therapy; Hematopoiesis; Hemostasis, Thrombosis, and Vascular Biology; Immunobiology; Neoplasia; Phagocytes; Red Cells; Transfusion Medicine; and Transplantation.
Plenary Papers. Definitive papers of exceptional scientific importance within the broad discipline of hematology will be considered for inclusion in the Plenary Papers category. Although the decision to highlight a paper in this section rests entirely with the Editors, authors may nominate their papers for this distinction. You may use the online Comments to the Editor-in-Chief box to call attention to the outstanding significance of the paper, if applicable.
Review Articles. Review articles are highly desired and are generally solicited by the Editor-in-Chief. A review article should focus on a topic of broad scientific interest, on recent advances in diagnosis and therapy, or on some other timely subject relevant to hematology. Such articles must be concise and critical and include appropriate references to the literature. These manuscripts should not exceed 5000 words in length, must include abstracts of 200 words or fewer, and must have no more than 100 references. The use of tables and color figures to summarize critical points is encouraged. Review Articles are reviewed by the Editors and other expert reviewers before a final publication decision is made, and revisions may be required. Guidelines for review articles are available on the Blood website at http://www.bloodjournal.org/misc/ifora2.shtml.
Perspectives. Perspectives on significant problems in the field of hematology are highly desired. Interested authors should correspond with the Editor-in-Chief to discuss the suitability of the proposed topic. The length should not exceed 2500 words, the abstract must not exceed 200 words, and references are limited to 50. Typically, Perspectives state the problem concisely, discuss opposing viewpoints, and make recommendations for further investigation.
Brief Reports. Short papers definitively documenting either experimental results or informative patient presentations will be considered for publication in this category. Document experimental results with a clear question in the introduction and then present definitive proof in the body of the text. Keep Materials and Methods succinct, using primarily cited work, but sufficiently informative to allow reproduction of the data. Combine the Results and Discussion sections and do not repeat the introductory comments. Brief Reports, should not exceed 1200 words in the text, 150 words in the abstract, 2 figures/tables, and 25 references.
Letters to the Editor. Comments on published articles or current hematology topics are welcome and will be published if appropriate. Letters should stay in the range of 300 to 500 words of text, 5 to 10 references, and 1 figure or table (if needed). Please include a brief title succinctly stating the topic of your Letter. Submission fees and page charges do not apply to Letters. Letters to the Editor are always screened, but may also be peer-reviewed or subjected to rebuttal by the authors of the initial article.
Data Supplements. The submission of data supplements, including videos, that enhance the understanding of the science discussed in the manuscript is encouraged. Data supplements should be submitted for peer review when the initial submission of the paper occurs. The Editors will review the supplemental material along with the manuscript, but acceptance of the manuscript does not guarantee ultimate acceptance of the supplement. Submit videos on a Zip disk in QuickTime 3.0 or higher format. Prepare on either a PC or a Macintosh computer. Submit at the desired reproduction size and length. To avoid excessive delays in downloading the files, make videos smaller than 5 MB (running between 30 and 45 seconds). Use QuickTime抯 揷ompress?option when preparing files to help control file size. Additionally, cropping frames and image sizes can significantly reduce file size. Files submitted can be looped to play more than once, provided file size does not become excessive. Authors will be notified if problems exist with videos as submitted and will be asked to take responsibility for any modifications. Please contact the Editorial office for specific requirements regarding all other formats for data supplements.
Organization of manuscript
Organize the content of your manuscripts as follows: Title Page, Introduction, Methods, Results, Discussion, Acknowledgments, References, Tables, Figure Legends, and Figures. Other editorial requirements follow:
Author statement. The corresponding author has the responsibility to submit a statement signed by all authors, indicating that all authors have reviewed the manuscript, agree with its content, and approve of its submission to Blood for publication consideration. The form can be found online at www.bloodjournal.org/misc/authstatement.shtml and should be faxed to the Editorial Office at 202-776- 0549. An equivalent statement approving the revision is required with the submission of a revised manuscript. The manuscript will not enter the review process unless a copy of the statement, including the signatures of all authors, has been received in the Editorial Office.
Declaration of commercial interest. For submitted papers that contain information affecting commercial products or potential products we require that the authors declare any financial interest in the product or in potentially competing products, above the level set by NIH disclosure guidelines (financial compensation greater than $10,000 per year, or stock holding greater than this amount). The policy applies to investors and consultants of the involved commercial venture. We also require that employees of companies whose commercial products are discussed reveal the fact of their employment.
Please note: It is the responsibility of the corresponding author to review this policy with all authors and to collectively list the appropriate commercial relationships. In such cases, a footnote will accompany the published paper, describing the applicable relationship as follows. Additionally, the information must be provided in the comments to the Editor-in-Chief during the online submission process.
1. One (several) of the authors (authors' initials) has (have) declared a financial interest in a company whose (potential) product was studied in the present work.
2. One (several) of the authors (authors' initials) has (have) declared a financial interest in a competitor of a company whose (potential) product was studied in the present work.
3. One (several) of the authors (authors' initials) is (are) employed by a company or a competitor of a company (X company) whose (potential) product was studied in the present work.
For work involving a biomedical product or potential product partially or wholly supported by corporate funding, a footnote will accompany the paper stating: This study was supported (in part) by research funding from (company name) to (authors' initials).
Title page. This page should contain the following: Article title ?Short title for running head (not to exceed 50 characters, including spaces between words) ? Full and accurate names of all authors ?Names of institutions in which work was done connected to the appropriate authors ?Note about research grants and any other financial support ?Corresponding author抯 full name, address, phone and fax number, and e-mail address ?Word counts. You should also choose an appropriate scientific heading from among the following: Chemokines; Clinical Observations, Interventions, and Therapeutic Trials; Gene Therapy; Hematopoiesis; Hemostasis, Thrombosis, and Vascular Biology; Immunobiology; Neoplasia; Phagocytes; Red Cells; Transfusion Medicine; and Transplantation. Please note that Brief Reports must also list a scientific heading on the title page.
Abstract. The abstract should contain 200 words or fewer (150 words or fewer for Brief Reports) and state the rationale, objectives, findings, and conclusions of the study.
Acknowledgments. Acknowledge support received from individuals, but not grant and other financial support. The latter should be stated on the title page (see above).
References. Include references in numerical order at the end of the article according to the order of citation in the text. Text citations of references should consist of superscript numbers. Format references per instructions at http://www.bloodjournal.org/misc/references.shtml. If you use citation software, check it carefully to ensure that it formats your references according to current Blood style.
Footnotes and abbreviations. Do not use footnotes; instead, use parenthetical statements within text, but sparingly. Abbreviations should be defined at first mention and thereafter applied consistently throughout the article. Do not use nonstandard abbreviations or abbreviate terms appearing fewer than 3 times. Give the chemical name of a compound after the first use of the trivial name. The trivial name may follow throughout the article. Abbreviate units of measure only when used with numbers.
Tables (see http://www.bloodjournal.org/misc/webuploadinginstructions.shtml for online uploading instructions). Each table should have a brief, specific, descriptive title, giving sufficient explanation to make the data intelligible without reference to the text. Number all tables and cite in numerical order in the text, using Arabic numerals.
Preparation of figures (see online uploading instructions). Cite figures in the text in numerical order using Arabic numerals. If figures are electron or photomicrographs, in color or in black-and-white, be prepared to submit 2 glossy originals as soon as the manuscript is accepted as a back-up to the online submission. The same applies to line drawings, for which high-quality laser figures are acceptable. Do not write on either the front or the back of photographs. Do not mount the figures, fasten them with paper clips, or store them in clasp envelopes. Type the name of the corresponding author, the figure number, and the orientation (top) on a label and attach the label to the back of the figure outside the image area.
Figure sizing for accepted manuscripts. For the print publication, lay out figures as compactly as is consistent with conveying the relevant data. Figures will be sized to fit the smallest possible space, but in order to prevent radical changes in figure content, prepare the figures in one of two sizes: 8.0 cm (1-column width) or, if necessary, 11.5 cm (1?column width). These instructions do not apply to figures submitted for online review and prepublication.
Figure legends. All legends must begin with a short descriptive sentence that sums up the intent and content of the data contained in the figure. This sentence should be in boldfont. A more detailed explanation of the data contained in the figure and/or its parts should follow. The detailed description should be in Roman type (ie, not in boldfont).
Color charges. Except for review articles, the cost of publishing color photographs will in part be borne by the authors. Charges to the author are currently assessed at $600 per figure even if the figure has multiple panels (A,B,C, etc.). You must decide at the submission stage whether you will pay for color in any or all of your figures. The alternative is to convert all or some of the figures to black-and-white before providing glossy originals for production.
Display of sequences. Prepare sequences as figures, not tables. This will ensure that proper alignment is preserved.
Submission of sequences to GenBank. Original DNA sequences reported in Blood must also be submitted to GenBank. Instructions for submission can be found at the following address: http://www.ncbi.nlm.nih.gov/Genbank/. An accession number should be supplied parenthetically at a relevant location in text.
Microarray databases. Blood supports the efforts of the Microarray Gene Expression Data Society to standardize the presentation of microarray data, and we recommend that authors follow their guidelines and checklist (http://www.mged.org/Workshops/MIAME/miame_checklist.html) In addition, the Journal strongly recommends the supplemental microarray data be deposited in a public database such as Gene Expression Omnibus (or GEO, at http://www.ncbi.nlm.nih.gov/geo/) or Array Express http://www.ebi.ac.uk/arrayexpress/, or submitted for peer-review with the initial submission of the manuscript.
Distribution of reagents. In January 1998, the Editors of Blood adopted the policy that any readily renewable resources mentioned in a Journal article not already obtainable from commercial sources shall be made available to all qualified investigators in the field. The policy stems from the long-standing scientific principle that authenticity requires reproducibility. Publication in Blood constitutes a de facto acceptance of this policy. Included are reagents that can be easily provided; specifically, nucleic acid sequences, cDNA and genomic clones, cell lines, and monoclonal antibody clones. Small amounts (sufficient for the replication of any in vitro work reported) of novel protein reagents are also considered easily transferable.
Although the Editors appreciate that many of the reagents mentioned in Blood are proprietary or unique, neither condition is considered adequate grounds for deviation from this policy. Suitable material transfer agreements can be drawn up between the provider and requester, but if a reasonable request is turned down and submitted to the Editor-in-Chief, the corresponding author will be held accountable. The consequence for noncompliance is simple: the corresponding author will not publish in Blood for the following 3 years.
Ethical principles for medical research involving human subjects. All studies that involve human subjects must abide by the rules of the appropriate Internal Review Board and the tenets of the (recently revised) Helsinki protocol (http://www.wma.net/e/policy/17-c_e.html).
Furthermore, all published studies that involve human subjects should not mention subjects' identifying information (eg, initials) unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. See the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" at http://www.icmje.org/index.html for further discussion.
Proofreading. Authors of accepted manuscripts will receive electronic page proofs directly from the printer and are responsible for proofreading and checking the entire article, including tables, figures, and references. Authors should correct only typesetting errors at this stage and may be charged for extensive alterations. Page proofs must be returned within 48 hours to avoid delays in publication. Send to:
Blood Production Office
1900 M Street, NW, Suite 200
Washington, DC 20036
Word counts. All manuscripts must include a total text word count and an abstract word count on the title page of the manuscript. The total text word count does not include title page, figure legends, references, or tables. Only under exceptional circumstances will papers containing more than 5000 words be considered, but under no circumstances will abstracts longer than 200 words be published. (The limits for Brief Reports are 1200 words of text and 150 words in abstracts.)
Revised manuscripts. In many cases, authors will be invited to make revisions to their manuscript. A revised manuscript must generally be received by the responsible Associate Editor within 3 months of the date on the decision letter or it will be considered a new submission. An extension can sometimes be negotiated with the Associate Editor. Please note that a new Author Statement, signed by all authors, must be submitted with the revision, certifying that all have read the revision and agree with its contents. A signed copyright transfer form must also be submitted with the revision. Both forms can be found in the Author Guide at http://www.bloodjournal.org and are available through Blood Manuscript Central. Fax form to 202-776-0549.
Prepublication in Blood's First Edition Papers
All original research accepted through Blood Manuscript Central and submitted for First Edition by the author will be prepublished online weekly in unedited form. Currently, Controversies in Hematology , Letters to the Editor, Inside Blood news items, Editorials, and Introductions to specially featured articles will not be prepublished as Frist Edition Papers. First Edition Papers are searchable in Medline, are citable, and establish publication priority. Prior to submitting a manuscript for First Edition prepublication, the submitting author must carefully review the entire manuscript, paying particular attention to list full and accurate names of all authors, include accurate institutional affilitations for each author, and include all figures, legends, and tables within the uploaded document. Figures may appear within the text itself or at the end of the manuscript. A prepublished First Edition Paper subsequently goes through the normal production process, which includes copyediting, composition, and proofreading. The edited paper is then published in its final form in the first available print and online issue of Blood. Please note that accepted data supplements are not prepublished and will only appear online at the time of final publication.
Fees and reprints
Processing fee. A processing fee of $50 is due on submission for Regular Manuscripts, Plenary Papers, Focus on Hematology papers, and Brief Reports. There is no processing fee for invited pieces, ie, Review Articles, Perspectives, Introduction to Focus on Hematology, or for Letters to the Editor. If a fee is required, please pay online at the time of submission, using a credit card. Payment by check, made out to 揃lood,?is possible for US residents. Payment must be in US dollars and checks must be drawn from a bank located in the United States of America. Please note that purchase orders, wire transfers, and checks drawn on foreign banks cannot be accepted for the processing fee. If a check is sent after the paper has been submitted online, make sure you mark the manuscript number you received on the check, and add a note with the full name of the corresponding author and at least the beginning of the title of the manuscript.
Page charges, color charges, and reprint fees. At the request of Blood, these fees are being handled by the printer, Cadmus Professional Communications, at the page proof stage. Authors receive a form for Reprints and Publication Fees, which must be used for ordering reprints and for paying page charges and color charges if color images were submitted and authorized by the author.
Page charges. The page charge is $50 per printed page for Regular Articles, Plenary Papers, Focus on Hematology papers, and Brief Reports. There are no page charges for any type of Review Article, Perspective, Introduction to Focus on Hematology, or Letter.
Reprint prices. A schedule of prices will be provided on the Reprint Order Form. Reprints must be ordered at the time the page proofs are reviewed. Later orders, especially of Reprints with color images, will be much more costly.
Color charges. To contribute to the high cost of printing in color, authors pay $600 per figure. Color charges will also be assessed for authors who submit a color image with a Letter to the Editor.
Payment options for reprints and publication fees. It is recommended that international authors pay by credit card (VISA or MasterCard); if they use a check, it must be drawn from a US bank and made out in US dollars. Domestic authors can use a credit card or pay by check; they will also have the option to present an Institutional Purchase Order. Make check out to Cadmus Professional Communications. The form for Reprints and Publications fees must be returned to the Printer at the following address:
Cadmus Professional Communications
Reprints and Publication Fees
PO Box 751903
Charlotte, NC 28275-1903
Additional information
Cover illustrations. Cover illustrations are chosen by the Editor-in-Chief. Authors who submit a manuscript are encouraged to include a color image they consider suitable for the cover of Blood (author must own copyright to the image.) The image must be sharp enough to allow magnification to the full size of the 6?x 11 in. image area. Add a brief caption explaining the content of the figure. Cover illustrations are published without charge to the author, but authors pay for any color figures used within their article. Authors will be notified by e-mail letter if their illustration has been selected.
Announcements. Announcements of meetings that are of interest to the readers of Blood should be sent to the Editor at least 3 months before the first day of the month of issue. Fees for announcements vary depending on their size and the number of insertions. Prices may be obtained by contacting the Blood Publishing Office (telephone: 202-776-0550; fax: 202-776-0551).
Advertisements/classified ads. Advertisements and classified ads should be sent to Blood抯 advertising representative, Cunningham Associates, 180 Old Tappan Rd, Old Tappan, NJ 07675; tel.: 201-767-4170; fax: 201-767-8065; e-mail: cunnasso@cybernex.net). For rates and data and other related information, see www.bloodjournal.org/misc/advertising.shtml or contact Cunningham Associates.
Copyright assignment. All material in Blood represents the opinions of the authors and does not reflect the opinions of The American Society of Hematology, the Editors, or the institutions with which the authors are affiliated. Authors submitting manuscripts do so with the understanding that if a manuscript is accepted, the copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to The American Society of Hematology, and that the corresponding author will be required to sign and submit a copyright transfer form on behalf of all authors at the Revision stage.
2. WEB UPLOADING INSTRUCTIONS
Complete web uploading instructions are available in the online version of the author guide at http://www.bloodjournal.org/misc/webuploadinginstructions.shtml. For additional uploading tips, see http://scholarone.com/author_instructions/060402_Blood_Upload_Instructions.html.
Editorial Board
Sanford J. Shattil, La Jolla, CA
Associate Editors:
Grover C. Bagby Jr
OHSU Cancer Institute
Oregon Health & Science University
3181 SW Sam Jackson Park Road
CR-145
Portland, OR 97201-3098
e-mail: bagby.blood@hematology.org
Willem E. Fibbe
Leiden University Medical Center
PO Box 9600
Building 1: C2-R
2300 RC Leiden
Netherlands
e-mail: hokeke@hematology.org
Malcolm K. Brenner
Center for Cell and Gene Therapy
Baylor College of Medicine
6621 Fannin Street, # 3-3320
Houston, TX 77030
e-mail: brenner.blood@hematology.org
Tomas Ganz
Department of Medicine
UCLA Center for the Health Sciences
CHS 37-055
10833 Le Conte Ave
Los Angeles, CA 90095
e-mail: ganz.blood@hematology.org
George J. Broze
Barnes-Jewish Hospital of St. Louis
216 S Kingshighway Blvd
Mail Code 90-20-662
Saint Louis, MO 63110-1026
e-mail: broze.blood@hematology.org
Jerome E. Groopman
Beth Israel Deaconess Medical Center
Harvard Institutes of Medicine
4 Blackfan Circle, Room 351
Boston, MA 02115
e-mail: blood@caregroup.harvard.edu
Michael A. Caligiuri
Division of Hematology and Oncology
Ohio State University
458A Starling-Loving Hall
320 West 10th Avenue
Columbus, OH 43210
e-mail: caligiuri.blood@hematology.org
Mohandas Narla
New York Blood Center
310 East 67th Street
New York, NY 10021
narla.blood@hematology.org" e-mail: narla.blood@hematology.org
Michael L. Cleary
Laboratory of Experimental Oncology
Department of Pathology
Stanford University Medical Center
300 Pasteur Dr, Lane Bldg, Room L235
Stanford, CA 94305-5324
e-mail: blood@cmgm.stanford.edu
Mortimer Poncz
Children's Hospital of Philadelphia
One Civic Center
Philadelphia, PA 19104
e-mail: poncz.blood@hematology.org
Cynthia Dunbar
National Heart, Lung and Blood Institute
National Institutes of Health
c/o 1900 M Street NW, Ste 200
Washington, DC 20036
e-mail: dunbar.blood@hematology.org
Martin S. Tallman
Northwestern University Medical School
Robert H. Lurie Comprehensive Cancer Center
676 N St Claire, Ste 850
Chicago, IL 60611-2927
e-mail: tallman.blood@hematology.org
刊名字顺( Alphabetical List of Journals):
返回页首 